|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM381313271 |
| 003 |
DE-627 |
| 005 |
20250307004707.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
241208s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110404
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1270.xml
|
| 035 |
|
|
|a (DE-627)NLM381313271
|
| 035 |
|
|
|a (NLM)39645159
|
| 035 |
|
|
|a (PII)S1521-6616(24)00513-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Alirezaylavasani, Amin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 11.12.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a Copyright © 2024. Published by Elsevier Inc.
|
| 520 |
|
|
|a Patients with Inflammatory Bowel Disease (IBD) undergoing immunosuppressive therapies face heightened susceptibility to severe COVID-19. An in-depth understanding of systemic inflammation and cellular immune responses after SARS-CoV-2 vaccination and breakthrough infections (BTI) is required for optimizing vaccine strategies in this population. While the prevalence of high serological responders post- third COVID-19 vaccine dose was lower, and the antibody waning was higher in IBD patients than in healthy donors (HD), IBD patients showed an increase in anti-RBD Wild Type IgG levels and cross-reactive Spike -specific memory B cells following BTI. However, there was no significant enhancement in cellular immune responses against anti-SARS-CoV-2 post-BTI, with responses instead characterized by activation of SARS-CoV-2 specific and also bystander CD8 T cells. These results suggest a complex interaction between chronic inflammation in IBD and the generation of new immune responses, highlighting the need for tailored vaccine regimens and anti-inflammatory therapies to boost cellular immunity against SARS-CoV-2
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Activation
|
| 650 |
|
4 |
|a Antibody waning
|
| 650 |
|
4 |
|a Hybrid immunity
|
| 650 |
|
4 |
|a IBD
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a TNF inhibitors
|
| 700 |
1 |
|
|a Egner, Ingrid Marie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dahl, Børresdatter
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chopra, Adity
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a de Matos Kasahara, Taissa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Goll, Guro Løvik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jahnsen, Jørgen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Grødeland, Gunnveig
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vaage, John Torgils
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lund-Johansen, Fridtjof
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Holter, Jan Cato
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Halvorsen, Bente
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jørgensen, Kristin Kaasen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Munthe, Ludvig A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kared, Hassen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 271(2024) vom: 05. Dez., Seite 110404
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:271
|g year:2024
|g day:05
|g month:12
|g pages:110404
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110404
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 271
|j 2024
|b 05
|c 12
|h 110404
|